Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

TARRYTOWN, N.Y., Oct. 28, 2020 /PRNewswire/ -- Today's data, involving an additional 524 patients from the ongoing Phase 2/3 trial, provides definitive final virology results and meets the clinical endpoint of reducing medical visits Regeneron has shared these results with the U.S. FDA,...

Regeneron's COVID-19 Outpatient Trial Prospectively Demonstrates that REGN-COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention

AbbVie

Amgen

bluebird bio

Bristol-Myers

Mustang Bio

Vertex Pharmaceuticals

Biotech stocks are always going to be here, in good times and bad. Let's look at a few that are worth considering on the long side.

7 Cutting-Edge Biotech Stocks for Tomorrow 

It's a low-risk option with lots of growth potential. What's not to like?

Is Regeneron the Best Coronavirus Stock to Buy Today?

Alexion Pharma

Biogen

Gilead Sciences

Moderna

The short interest data are out for October 15, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.

Major Biotechs Have Short Sellers Looking Both Ways

In this article we will check out the progression of hedge fund sentiment towards Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds have access to expert networks and get tips from industry insiders. They also employ numerous Ivy League graduates and MBAs. Like everyone else, hedge funds perform miserably at times, but their consensus picks have historically outperformed the market after risk adjustments.

Were Hedge Funds Right About Embracing Regeneron Pharmaceuticals Inc (REGN)?

BioNTech SE

Pfizer

It could translate to good news for biotechs with COVID-19 therapies.

Here's the Biggest Misconception About Coronavirus Vaccines

Everyone has been talking about Regeneron since President Trump praised its investigational coronavirus treatment.

Is Regeneron a Buy Before Nov. 3?

NEW YORK--(BUSINESS WIRE)-- #REGN--Scott+Scott Attorneys at Law LLP Continues to Investigate Regeneron Pharma, Inc.'s Directors and Officers for Breach of Fiduciary Duty (REGN)

Scott+Scott Attorneys at Law LLP Continues to Investigate Regeneron Pharmaceuticals, Inc.'s Directors and Officers for Breach of Fiduciary Duty (REGN)

MIAMI and BOCA RATON, Fla., Oct. 21, 2020 /PRNewswire/ -- Since 2015, Xera Med Research has been leading the way in assisting pharmaceutical companies in search of patient-focused treatments in the areas of autoimmune, infectious diseases, women's health, and now Coronavirus SARS-CoV2...

Xera Med Research Is Making Advances In Assisting Regeneron In Their Antibodies Cocktail Clinical Trials Participation With Upwards Of 30 Patients To Date

Eli Lilly

How Monoclonal Antibodies Can Treat COVID-19 and What the Data Says About Vaccines

How Should Investors Play COVID-19 Stocks?

Manufacturing will play a big role in the eventual winner.

How Regeneron's Coronavirus Antibody Treatment Differs From Convalescent Plasma

Regeneron (REGN) gets positive CHMP opinion for Dupixent, recommending extending the approval in the European Union to include children aged 6 to 11 years with severe atopic dermatitis.

Regeneron's (REGN) Dupixent Gets Positive CHMP Opinion for Dermatitis

Biotech company Regeneron has seen its stock price rally by over 55% this year with the stock currently trading at about $600 per share, due to anticipation surrounding the company's experimental Covid treatments. Regeneron has gotten a lot of attention in recent weeks, amid news that.

After 55% Rise, Is Regeneron Stock Poised To Decline?

BioMarin Pharmaceutical

Insmed

United Therapeutics

Earnings season is upon us and investors are pining for information about which stocks and sectors will do well.

7 Large Biotechs Expected to Outperform This Earnings Season

Regeneron (REGN) gets FDA nod for its triple antibody cocktail for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients.

Regeneron's (REGN) Inmazeb Ebola Treatment Gets FDA Approval

Regeneron Reports Positive  Data, And Other News: The Good, Bad And Ugly Of Biopharma

The United States Food and Drug Administration approved Regeneron Pharmaceuticals, Inc's (NASDAQ: REGN) drug Inmazeb for the treatment of Ebola in both adults and children on Wednesday. What Happened: Inmazeb is the first-ever drug approved for the treatment of the infection caused by the Zaire ebolavirus, according to the FDA.

Regeneron's Inmazeb Becomes First Ebola Treatment To Get FDA Approval

Regeneron Pharmaceuticals Inc. REGN said late Wednesday the Food and Drug Administration approved its treatment for the Ebola virus. The biotech company said the agency approved Inmazeb, the first FDA-approved treatment for Ebola.

Regeneron gets FDA approval for Ebola drug

TARRYTOWN, N.Y., Oct. 14, 2020 /PRNewswire/ -- In a large clinical trial, Inmazeb showed superiority compared to other investigational agents (ZMapp and remdesivir) with respect to mortality; treatment was most effective when given early in the course of disease1 Inmazeb (atoltivimab,...

Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb®) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus)

Sanofi

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) disclosed that their asthma drug Dupixent (dupilumab) met its primary and all key secondary endpoints in randomized Phase 3 clinical trials demonstrating improved lung functions in children aged between six to 11 years. Data from trial results hint that Dupixent holds a lot of promise for children (aged between six to 11 years) with uncontrolled moderate-to-severe asthma.

Sanofi, Regeneron Report Positive Phase 3 Results For Asthma Drug Dupixent's Use In Children

The short interest data are out for September 30, the most recent settlement date.

Short Sellers Need to Find a Clue on Major Biotechs

Our indicative theme on Covid-19 Treatment Stocks – which includes biotech and pharma companies selling or developing treatments for the novel Coronavirus – is up by 16% year-to-date, compared to the S&P 500 which is up about 4%. While the long-term demand for Covid-19 treatments is not clear.

News for Regeneron Pharmaceuticals Stock (REGN)